H.R. 10857 has not moved since its introduction on Oct 22, 2026, with one cosponsor, a Republican
To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
IntroducedOct 22, 2026
Reported—
Passed one chamber—
Passed both—
Law—
What it changes · CRS summary
CRS has not published a summary of this bill yet.
Context
- Committees
- House Energy and Commerce Committee
House Ways and Means Committee - Sponsor
- 0 of 25 bills enacted since 2013
- Latest action
- Oct 22, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Records
- Congress.gov
Exhibit 1Passage odds band at each stage, rated when the bill reached it [4]
Related bills · 0
The bill status record lists no related bills.
Exhibit 2Articles naming the bill per day, last 90 days, US sources [3]